Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma

The article describes the experience in effective use of the second-generation EGFR II blocker in palliative target therapy of EGFRnegative lung adenocarcinoma. The use of afatinib in the fifth-line palliative therapy of EGFR-negative lung adenocarcinoma allowed us to achieve a significant positive response to therapy in the lungs and improve the patient’s quality of life.